WO2005053663A3 - Norepinephrine reuptake inhibitors useful for treatment of cognitive failure - Google Patents

Norepinephrine reuptake inhibitors useful for treatment of cognitive failure Download PDF

Info

Publication number
WO2005053663A3
WO2005053663A3 PCT/US2004/037195 US2004037195W WO2005053663A3 WO 2005053663 A3 WO2005053663 A3 WO 2005053663A3 US 2004037195 W US2004037195 W US 2004037195W WO 2005053663 A3 WO2005053663 A3 WO 2005053663A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
reuptake inhibitors
norepinephrine reuptake
inhibitors useful
cognitive failure
Prior art date
Application number
PCT/US2004/037195
Other languages
French (fr)
Other versions
WO2005053663A2 (en
Inventor
Alan Kramer Hatfield
Franklin Porter Bymaster
David Lee Mckinzie
Tina Marie Tucker
Kirk Matthew Keaffaber
Calvin Russell Sumner
Paula Terese Trzepacz
Albert John Allen
Douglas Kenneth Kelsey
David Michelson
Donald Richard Gehlert
Charles Renkin Yang
Original Assignee
Lilly Co Eli
Alan Kramer Hatfield
Franklin Porter Bymaster
David Lee Mckinzie
Tina Marie Tucker
Kirk Matthew Keaffaber
Calvin Russell Sumner
Paula Terese Trzepacz
Albert John Allen
Douglas Kenneth Kelsey
David Michelson
Donald Richard Gehlert
Charles Renkin Yang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Alan Kramer Hatfield, Franklin Porter Bymaster, David Lee Mckinzie, Tina Marie Tucker, Kirk Matthew Keaffaber, Calvin Russell Sumner, Paula Terese Trzepacz, Albert John Allen, Douglas Kenneth Kelsey, David Michelson, Donald Richard Gehlert, Charles Renkin Yang filed Critical Lilly Co Eli
Publication of WO2005053663A2 publication Critical patent/WO2005053663A2/en
Publication of WO2005053663A3 publication Critical patent/WO2005053663A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Selective norepinephrine reuptake inhibitors are used to treat cognitive failure.
PCT/US2004/037195 2003-11-24 2004-11-24 Norepinephrine reuptake inhibitors useful for treatment of cognitive failure WO2005053663A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US52445003P 2003-11-24 2003-11-24
US60/524,450 2003-11-24
US52478103P 2003-11-25 2003-11-25
US60/524,781 2003-11-25

Publications (2)

Publication Number Publication Date
WO2005053663A2 WO2005053663A2 (en) 2005-06-16
WO2005053663A3 true WO2005053663A3 (en) 2005-08-11

Family

ID=34657156

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/037195 WO2005053663A2 (en) 2003-11-24 2004-11-24 Norepinephrine reuptake inhibitors useful for treatment of cognitive failure

Country Status (1)

Country Link
WO (1) WO2005053663A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056497A1 (en) * 2007-01-31 2010-03-04 Dainippon Sumitomo Pharma Co., Ltd Amide derivative
AU2008339351B2 (en) 2007-12-19 2013-02-28 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic heterocyclic derivative
JP5331883B2 (en) 2009-06-24 2013-10-30 大日本住友製薬株式会社 N-substituted cyclic amino derivatives

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2370732A1 (en) * 1976-11-16 1978-06-09 Anphar Sa POLYSUBSTITUTE DERIVATIVES OF PIPERIDINE, THEIR METHODS OF PREPARATION AND THEIR APPLICATION AS MEDICINAL PRODUCTS
GB2167407A (en) * 1984-11-22 1986-05-29 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
WO2001066521A1 (en) * 2000-03-06 2001-09-13 Acadia Pharmaceuticals, Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
WO2004000808A2 (en) * 2002-06-24 2003-12-31 Acadia Pharmaceuticals Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2004030668A1 (en) * 2002-10-04 2004-04-15 Ucb, S.A. 4-aminopiperidine derivatives, processes for their preparation and their use as medicaments
WO2004052858A2 (en) * 2002-12-06 2004-06-24 Eli Lilly And Company Inhibitors of monoamine uptake

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2370732A1 (en) * 1976-11-16 1978-06-09 Anphar Sa POLYSUBSTITUTE DERIVATIVES OF PIPERIDINE, THEIR METHODS OF PREPARATION AND THEIR APPLICATION AS MEDICINAL PRODUCTS
GB2167407A (en) * 1984-11-22 1986-05-29 Erba Farmitalia Enantiomers of phenoxy derivatives of benzyl morpholine and salts thereof
WO2001066521A1 (en) * 2000-03-06 2001-09-13 Acadia Pharmaceuticals, Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
WO2004000808A2 (en) * 2002-06-24 2003-12-31 Acadia Pharmaceuticals Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2004030668A1 (en) * 2002-10-04 2004-04-15 Ucb, S.A. 4-aminopiperidine derivatives, processes for their preparation and their use as medicaments
WO2004052858A2 (en) * 2002-12-06 2004-06-24 Eli Lilly And Company Inhibitors of monoamine uptake

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THOMAS RYCKMANS ET AL: "First Dual NK1 Antagonists-Serotonin Reuptake Inhibitors: synthesis and SAR of a New Class of Potential Antidepressants", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 12, no. 2, 2002, pages 261 - 264, XP002974382, ISSN: 0960-894X *

Also Published As

Publication number Publication date
WO2005053663A2 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
WO2006023649A3 (en) Treatment of severe multiple sclerosis
WO2004047830A3 (en) Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor and the use of said composition for treating bladder dysfunction
EA200700851A1 (en) OBTAINING AND APPLICATION OF BIPHENYL-4-ILKARBONYLAMINO ACID DERIVATIVES FOR TREATMENT OF OBESITY
WO2006015159A3 (en) Potassium channel inhibitors
WO2007087468A3 (en) Adiponectin for treatment of various disorders
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
TW200607513A (en) Certain chemical entities, compositions, and methods
WO2006052718A3 (en) Farnesyltransferase inhibitors for treating sepsis
WO2007024971A3 (en) Hedgehog pathway antagonists to treat disease
DE602005012481D1 (en) 2,7-SUBSTITUTED 5-AMINO-4-HYDROXY-8- (1H-INDOL-5-YL) -OCTANAMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF BLOOD HIGH PRESSURE
MY144970A (en) Heterocyclic compounds
WO2006063294A3 (en) Novel inhibitors of histone deacetylase for the treatment of disease
WO2006055871A3 (en) Treatment for multiple sclerosis
WO2007112121A3 (en) Tetracycline compounds and methods of treatment
NO20076186L (en) Mitotic kinesin inhibitors and methods for their use
ATE399557T1 (en) SELECTIVE NOREPINEPHRINE REUPPOST INHIBITORS FOR THE TREATMENT OF HOT FLASHES
MY136367A (en) Treatment of cognitive failure
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
WO2006014877A3 (en) Potassium channel inhibitors
WO2004052858A3 (en) Inhibitors of monoamine uptake
WO2001066101A3 (en) Treatment of psoriasis
WO2005124563A9 (en) Compounds and kits for treating muscle disorders and methods of use thereof
WO2005053663A3 (en) Norepinephrine reuptake inhibitors useful for treatment of cognitive failure
WO2004098522A3 (en) Gemini vitamin d3 compounds and methods of use thereof
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase